Skip to Main Content

CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients

Conditions

COVID-19 Inpatient | COVID-19 Outpatient

Phase COVID-II

What is the purpose of this trial?

This is a randomized, blinded phase 2 trial that will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms requiring oxygen supplementation.

  • Trial with
    Yale Cancer Center
  • Start Date
    08/30/2020
  • End Date
    01/30/2023
Trial Image

For more information about this study, contact:

Lisa D. Baker

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    09/08/2020
  • Study HIC
    #2000028181